Profile data is unavailable for this security.
About the company
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
- Revenue in CHF (TTM)577.32m
- Net income in CHF111.86m
- Incorporated1971
- Employees2.01k
- LocationBachem Holding AGHauptstrasse 144BUBENDORF 4416SwitzerlandCHE
- Phone+41 619352333
- Fax+41 619352324
- Websitehttps://www.bachem.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dottikon ES Holding AG | 338.23m | 86.17m | 3.32bn | 694.00 | 37.99 | 3.88 | 30.93 | 9.81 | 6.24 | 6.24 | 24.49 | 61.10 | 0.3135 | 0.6339 | 5.39 | 498,861.30 | 7.99 | 7.48 | 9.58 | 8.48 | 67.58 | 78.94 | 25.48 | 22.35 | 1.65 | 101.25 | 0.1062 | -- | 26.80 | 15.09 | 47.94 | 27.70 | 30.78 | -- |
Siegfried Holding AG | 1.27bn | 112.06m | 4.10bn | 3.93k | 34.53 | 4.60 | 21.11 | 3.22 | 26.28 | 26.28 | 298.23 | 197.49 | 0.6958 | 2.27 | 3.14 | 323,288.60 | 6.17 | 6.51 | 7.67 | 7.98 | 25.20 | 23.24 | 8.86 | 9.06 | 1.39 | 7.93 | 0.3468 | 15.26 | 3.41 | 9.87 | -28.16 | 18.34 | 17.95 | 6.72 |
Krka d.d. Novo Mesto | 1.77bn | 307.21m | 4.16bn | 11.78k | 12.77 | 1.85 | 10.03 | 2.35 | 10.14 | 10.14 | 58.36 | 70.02 | 0.6627 | 1.35 | 3.96 | 153,343.90 | 11.51 | 12.64 | 13.75 | 15.12 | 56.84 | 57.29 | 17.37 | 18.71 | 2.54 | 19.99 | 0.0055 | -- | 5.18 | 6.28 | -13.58 | 12.45 | 8.35 | -- |
Laboratorios Farmaceuticos ROVI SA | 811.71m | 166.68m | 4.26bn | 2.11k | 25.17 | 7.75 | 22.77 | 5.25 | 3.20 | 3.20 | 15.58 | 10.41 | 0.9883 | 1.04 | 5.13 | 392,946.00 | 20.29 | 18.90 | 28.88 | 25.58 | 59.35 | 59.82 | 20.53 | 20.13 | 0.8575 | -- | 0.1075 | 33.60 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
Richter Gedeon Vegyeszeti Gyar Nyrt | 2.00bn | 393.72m | 4.28bn | 12.17k | 10.80 | 1.50 | 8.17 | 2.14 | 857.81 | 857.79 | 4,349.05 | 6,173.08 | 0.5931 | 1.71 | 4.08 | -- | 11.83 | 11.64 | 13.39 | 13.28 | 64.75 | 58.18 | 19.95 | 18.93 | 3.12 | 7.49 | 0.0159 | 39.70 | 0.2993 | 12.57 | -6.05 | 35.06 | 15.59 | 33.38 |
Hikma Pharmaceuticals Plc | 2.60bn | 171.74m | 4.77bn | 8.97k | 27.80 | 2.39 | 11.69 | 1.83 | 0.6765 | 0.6765 | 10.23 | 7.87 | 0.6284 | 1.76 | 3.67 | 253,693.80 | 4.20 | 8.19 | 5.72 | 11.30 | 48.94 | 50.29 | 6.68 | 13.77 | 0.9029 | 7.68 | 0.3503 | 36.71 | 14.22 | 6.73 | 1.06 | -7.59 | 7.97 | 4.54 |
Orion Oyj | 1.16bn | 212.15m | 4.77bn | 3.63k | 22.28 | 5.44 | 18.46 | 4.09 | 1.55 | 1.55 | 8.49 | 6.34 | 0.8088 | 1.57 | 5.56 | 327,588.10 | 14.72 | 19.47 | 18.03 | 24.16 | 55.30 | 59.38 | 18.20 | 20.71 | 1.75 | 94.79 | 0.1835 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
DiaSorin SpA | -97.85bn | -97.85bn | 4.87bn | 3.28k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.14 | -- | 14.79 | -- | 67.40 | -- | 23.33 | -- | -- | -- | 23.89 | 9.98 | 16.38 | -22.53 | 11.49 | 21.76 | 5.29 |
Grifols SA | 6.45bn | 58.04m | 4.98bn | 23.74k | 92.04 | 0.9668 | 8.18 | 0.7723 | 0.0901 | 0.0901 | 9.80 | 8.58 | 0.3068 | 1.23 | 9.86 | 277,627.00 | 0.8408 | 2.39 | 1.06 | 3.04 | 37.84 | 40.26 | 2.74 | 7.54 | 1.29 | 1.56 | 0.5593 | -- | 8.71 | 8.00 | -71.52 | -36.98 | -0.8127 | -- |
Zealand Pharma A/S | 44.98m | -92.35m | 5.60bn | 253.00 | -- | 24.98 | -- | 124.49 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
BACHEM HOLDING AG | 577.32m | 111.86m | 6.34bn | 2.01k | 56.40 | 4.80 | 40.37 | 10.98 | 1.50 | 1.50 | 7.73 | 17.61 | 0.3765 | 1.23 | 3.33 | 287,794.60 | 7.29 | 8.85 | 8.17 | 10.28 | 30.65 | 31.63 | 19.38 | 19.74 | 3.04 | 29.80 | 0.0003 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
Croda International Plc | 1.94bn | 195.34m | 7.74bn | 5.85k | 39.68 | 2.88 | 22.72 | 4.00 | 1.22 | 1.22 | 12.12 | 16.85 | 0.4713 | 2.40 | 4.39 | 289,559.10 | 4.79 | 10.80 | 5.42 | 12.51 | 43.08 | 46.41 | 10.16 | 18.64 | 1.77 | 17.07 | 0.2307 | 43.44 | -18.90 | 4.09 | -73.66 | -6.42 | 12.78 | 4.11 |
Swedish Orphan Biovitrum AB (publ) | 1.88bn | 205.17m | 8.22bn | 1.79k | 36.79 | 2.73 | 17.20 | 4.36 | 7.40 | 7.40 | 68.65 | 99.68 | 0.3497 | 1.38 | 4.25 | -- | 3.81 | 5.93 | 5.20 | 7.60 | 77.58 | 77.41 | 10.88 | 16.61 | 0.4607 | 4.04 | 0.3769 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Qiagen NV | 1.78bn | 308.50m | 8.55bn | 5.97k | 27.93 | 2.48 | 17.31 | 4.82 | 1.41 | 1.41 | 8.12 | 15.89 | 0.3169 | 1.93 | 5.38 | 304,232.90 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
Ipsen SA | 3.24bn | 603.86m | 8.96bn | 5.07k | 14.77 | 2.36 | 12.89 | 2.77 | 7.39 | 7.72 | 39.66 | 46.29 | 0.554 | 1.99 | 5.23 | -- | 10.48 | 9.71 | 13.93 | 13.33 | 82.72 | 82.76 | 18.91 | 16.02 | 0.989 | 30.43 | 0.1106 | 19.87 | 4.75 | 7.08 | 4.03 | 9.75 | -8.65 | 3.71 |
Holder | Shares | % Held |
---|---|---|
VV Verm�gensverwaltung AGas of 29 Dec 2023 | 3.55m | 4.73% |
Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 3.23m | 4.31% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 1.10m | 1.46% |
Capital Research & Management Co. (Global Investors)as of 31 Dec 2023 | 924.17k | 1.23% |
Z�rcher Kantonalbank (Investment Management)as of 31 Jan 2024 | 852.03k | 1.14% |
Norges Bank Investment Managementas of 31 Dec 2023 | 719.50k | 0.96% |
UBS Asset Management Switzerland AGas of 05 Mar 2024 | 634.34k | 0.85% |
Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 541.99k | 0.72% |
Premier Fund Managers Ltd.as of 30 Nov 2023 | 516.18k | 0.69% |
BlackRock Fund Advisorsas of 07 Mar 2024 | 511.25k | 0.68% |